香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年8月1日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 证券代码：300759 证券简称：康龙化成 公告编号：2025-039 康龙化成（北京）新药技术股份有限公司 关于 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-039 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 占其 | 占公 | 情况 | | 情况 | | | | 持股数量 | 持股 | 和解质押 | 和解质押 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | 股东名称 | | 比例 | 前质押股 | 后质押股 | 股份 | 股本 | 份限售和 | 质押 | | 质押 | | | （股） | | | | | | | | 份限售和 | | | | | (%) | 份数量 | 份数量 | 比例 | 比例 | 冻结、标 | 股份 | 冻结数量 | 股份 | | | | | （股） | （股） | (%) | (%) | 记数量 | 比例 | （股） | 比例 | | | | | | | | | （股） | (%) | | (%) | | 楼小强 | 60,540,050 | 3 ...

Core Viewpoint - The CRO leader, Zhaoyan Pharmaceutical, has nearly doubled in value, with a more than 50% increase in July, driven by signs of recovery in the CXO market and successful turnaround due to the value of laboratory monkeys [1][2]. Group 1: Market Recovery Signals - The market has observed a recovery signal in the CXO sector, with Zhaoyan Pharmaceutical successfully turning losses into profits by leveraging the value of laboratory monkeys [2][3]. - The increase in monkey prices is attributed to a tightening supply and recovering demand, indicating a potential new cycle in the market [12][24]. Group 2: Financial Performance - Zhaoyan Pharmaceutical's mid-year performance forecast indicates expected revenue between 630 million to 702 million yuan, a year-on-year decline of approximately 17.3% to 25.2%, but a net profit turnaround with estimates between 50.32 million to 75.49 million yuan, largely driven by biological asset value changes [8][9]. Group 3: Supply and Demand Dynamics - The supply of laboratory monkeys is constrained by long breeding cycles and an aging population, with a significant increase in the proportion of breeding females over 8 years old, leading to a decline in reproductive rates [17][20]. - The current supply of laboratory monkeys is around 25,000 to 28,000 annually, while actual demand approaches 40,000, indicating a significant supply-demand gap [25]. Group 4: Future Outlook - The industry faces challenges in increasing monkey supply due to aging populations and long breeding cycles, with any potential recovery in supply expected to take several years [26][27]. - The interplay between biological cycles and market demand suggests that the industry may be on the brink of a new cycle, but significant hurdles remain in achieving a sustainable supply of laboratory monkeys [32][33].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...

Core Viewpoints - The market is adopting a wait-and-see attitude due to trade policy uncertainties, with the Hang Seng Index falling below 25,000 points, down 1.6% to 24,773.33 points [2] - Southbound funds have seen a net inflow of HKD 13.126 billion, maintaining a level above HKD 8 billion for five consecutive days [2] Market Performance - The major indices in the Hong Kong stock market continued to decline, with the Hang Seng Index, the Hang Seng China Enterprises Index, and the Hang Seng Technology Index all experiencing losses [2] - The total market turnover increased to HKD 320.633 billion, with the short-selling amount rising to HKD 51.314 billion, accounting for 17.607% of the total turnover [2] Sector Analysis - The luxury goods, Hong Kong retail, and local consumption sectors showed significant declines, indicating pressure on consumer spending and related company performance [4] - Prada's stock dropped 8% following its H1 2025 financial report, leading the sector's decline, while Chow Tai Fook and Samsonite fell 4.5% and 2.9%, respectively [4] - Other consumer-related stocks, including beer, home appliances, food, and automotive sectors, also performed poorly, reflecting a general decline in consumer confidence [4] Electricity Sector Insights - In June, the total electricity consumption in society grew by 5.4% year-on-year, with a notable increase in the third sector and residential electricity consumption [10] - The cumulative electricity consumption from January to June reached 48,418 billion kilowatt-hours, with a year-on-year growth of 3.7% [10] - High-tech industries showed a higher electricity consumption growth rate, with the new energy vehicle manufacturing sector growing by 28.7% year-on-year [11] Investment Recommendations - The report suggests that investors consider undervalued, high-dividend, and fast-growing electricity operators such as China Resources Power and China Power [13]

格隆汇8月1日丨根据联交所最新权益披露资料显示，2025年7月28日，康龙化成(03759.HK)遭JPMorgan Chase & Co.以每股均价23.1782港元减持好仓80.06万股，涉资约1855.54万港元。 减持后，JPMorgan Chase & Co.最新持好仓数目为17,567,591股，持好仓比例由6.09%下降至5.82%。 来源：格隆汇APP | 夜格序线 | 大身東/愛車/最高行政人員名稱作出技露的 寶入/費出或涉及0 種股的平河量 | | | | | | 持法律法的股份數目 作已發行的 利國唯生的日期 相談我的 禮權頂轉發。 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | STETE | 限分割日 | | | | ( 跨書隨上述*註 南投開機股(日/月7年) 權益 | | | | | | | -22 17 | | HERE BEAR | | | | | | | | | 196 | | CS20250731E00117 | JPMorgan Chase & Co. | 1201(L) | | 800,553(L) ...

香港联交所最新资料显示，7月28日，摩根大通减持康龙化成（300759）(03759)80.0553万股，每股作价 23.1782港元，总金额约1855.54万港元。减持后最新持股数目约为1756.76万股，最新持股比例为 5.82%。 ...

中欧医疗健康混合A股票持仓前十占比合计54.73%，分别为：药明康德（10.39%）、恒瑞医药 （9.69%）、康龙化成（5.05%）、科伦药业（4.97%）、泰格医药（4.78%）、凯莱英（4.67%）、百利 天恒（4.11%）、信立泰（4.02%）、百济神州-U（3.66%）、新诺威（3.39%）。 公开资料显示，中欧医疗健康混合A基金成立于2016年9月29日，截至2025年6月30日，中欧医疗健康混 合A规模156.38亿元，基金经理为葛兰、赵磊。 金融界2025年7月31日消息，中欧医疗健康混合A(003095) 最新净值1.9928元，下跌0.81%。该基金近1个 月收益率17.30%，同类排名128|1534；近6个月收益率31.97%，同类排名139|1493；今年来收益率 27.04%，同类排名212|1481。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22 ...

智通财经APP获悉，香港联交所最新资料显示，7月28日，摩根大通减持康龙化成(03759)80.0553万股， 每股作价23.1782港元，总金额约1855.54万港元。减持后最新持股数目约为1756.76万股，最新持股比例 为5.82%。 ...

Core Viewpoint - After a historic 10-day rally, the largest medical ETF in A-shares (512170) experienced a pullback, with the index dropping over 1% on July 31, 2023, and the medical sector also declining [1][4]. Market Performance - The medical ETF (512170) recorded a daily fluctuation of 2.67%, with a trading volume of 1.02 billion yuan, remaining at a relatively high level [1]. - In July, the medical ETF saw a cumulative increase of 11.48%, outperforming the Shanghai Composite Index (+3.74%) and the ChiNext Index (+8.14%) [2][4]. Sector Analysis - Major CXO stocks, including WuXi AppTec, experienced significant declines, with WuXi AppTec down 2.61% and a trading volume of 9.499 billion yuan, marking a near four-month high [4]. - Other medical device giants like Mindray Medical and Aier Eye Hospital also saw declines of over 2% [4]. Policy and Industry Outlook - There is a growing support from the government for innovative medical devices, as indicated by recent meetings held by the National Healthcare Security Administration [6]. - The policy shift aims to alleviate low-price competition in the industry and accelerate the development of high-end domestic medical devices [6]. - Public funds have increased their allocation to the medical sector, with the top ten A-share funds holding 11.51% in the medical sector, up 1.51% from the previous quarter [6]. Investment Opportunities - The medical ETF (512170) is highlighted as a potential investment opportunity, focusing on "medical devices + medical services" and is closely related to AI in healthcare [7]. - The first pharmaceutical ETF (562050) is also recommended, focusing on 50 leading pharmaceutical companies, emphasizing innovative drugs and high-barrier generic drugs [7].